ClinicalTrials.gg
Biological

Pneumococcal 21-Valent Conjugate Vaccine clinical trials

Also written PCV21.

Its developmentBy Merck and Sanofi, step by step18 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.
studies test it
19
open now
3
in phase 3
16
first study started
2019

How each study uses Pneumococcal 21-Valent Conjugate Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Pneumococcal 21-Valent Conjugate Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Jun 2024 · CAPVAXIVE · BLA 125814 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

V116
11
Pneumococcal 21-valent Conjugate Vaccine
10
PCV21 vaccine
5
515
5
Polyvalent pneumococcal conjugate vaccine (pPCV)
2

Development codes

PCV21
3

Studies by the year they started

19 studies that test it; most in 2022 (6)

Studies that test Pneumococcal 21-Valent Conjugate Vaccine, by start year
YearStudies
20191
20211
20226
20232
20242
20254
20263

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1
Phase 3
16
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 18 · Other 1

Merck Sharp & Dohme LLC (11) · Sanofi (5) · Sanofi Pasteur, a Sanofi Company (2) · VA Sierra Nevada Health Care System (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8, 7 in phase 3

Studies that test Pneumococcal 21-Valent Conjugate Vaccine, phase 3 first.

Studies

Open first, then newest update. How each study uses Pneumococcal 21-Valent Conjugate Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 19

Given beside what is tested · 1 — Pneumococcal 21-Valent Conjugate Vaccine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Pneumococcal 21-Valent Conjugate Vaccine